Starling Bank swoops in £270m share sale to global investors originalfm.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from originalfm.com Daily Mail and Mail on Sunday newspapers.
Share
The 2020s are on course to become the decade of the special purpose acquisition companies (SPACs), also known as blank check or shell companies. SPACs are set to outpace IPOs once again in 2021, after a record year that saw SPACs mature from a once obscure method of going public to a rabid, flavor-of-the-month frenzy amidst both institutional and retail investors.
The year of COVID-19 saw 227 SPACs top traditional IPOs for the first time in history, raising $76 billion, compared to 67 billion raised from traditional IPOs. The first two months of 2021 have so far generated 144 SPACs, raising $44 billion. Digital Health has certainly ridden the recent SPAC wave, with yet a few more splashes yet to come.
Israeli chip co Xsight Labs raises over $100m
The Kiryat Gat-based company aims to deliver end-to-end connectivity solutions for cloud infrastructure.
Israeli fabless semiconductor Xsight Labs has announced the closing of its Series D financing round led by Valor Equity Partners and Atreides Management with the participation of new investors Fidelity Management & Research and Accton Technology and existing investors Battery Ventures, Intel Capital, M12 Microsoft’s Venture Fund and Xilinx, increased their investments.
RELATED ARTICLES
The specific amount raised by Xsight Labs was not disclosed but founding investor Avigdor Willenz said, Xsight Labs’ Series D was significantly oversubscribed and is the largest round ever raised by our group. The completion of this round will help Xsight Labs execute its ambitious vision of delivering end-to-end connectivity solutions for cloud infrastructure.
Allogeneic cell therapy player Century raises $160m in funds to advance pre-clinical pipeline biopharma-reporter.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biopharma-reporter.com Daily Mail and Mail on Sunday newspapers.